| Main Street Medical Associates | |
|
214 E Main St Morehead KY 40351-1620 | |
| (606) 784-8682 | |
| Not Available |
| Full Name | Main Street Medical Associates |
|---|---|
| Speciality | Family Medicine |
| Location | 214 E Main St, Morehead, Kentucky |
| Authorized Official Name and Position | Wynetta J. Fletcher (OWNER) |
| Authorized Official Contact | 6067848682 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Main Street Medical Associates 214 E Main St Morehead KY 40351-1620 Ph: (606) 784-8682 | Main Street Medical Associates 214 E Main St Morehead KY 40351-1620 Ph: (606) 784-8682 |
| NPI Number | 1003496902 |
|---|---|
| Provider Enumeration Date | 04/13/2021 |
| Last Update Date | 07/03/2023 |
| Certification Date | 07/03/2023 |
| Medicare PECOS PAC ID | 8527467034 |
|---|---|
| Medicare Enrollment ID | O20210602002318 |
News Archive
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.
T cells are key players in the immune response to HIV, which are able to delete infected cells. This capacity is used for vaccine development against HIV. "To date however, success of this strategy remains elusive. Our understanding of T cell efficacy is still limited, and we need to identify precise T cell correlates of protection that could guide rationale vaccine design", says Victor Appay, Group leader HIV Pathogenesis and Immunosenescence, Hopital Pitie-Salpetriere, Paris, at the 2nd European Congress of Immunology ECI 2009 in Berlin.
VertiFlex, Inc., a leading innovator of advanced minimally invasive spinal surgery technologies, today announced that the U.S. Patent and Trademark Office has awarded five additional key patents covering the design and implantation method for its unique interspinous spacer technology. The five U.S. patent numbers are 8,012,207, 8,123,807, 8,123,782, 8,128,662, and 8,152,837.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003496902 | NPI | - | NPPES |
| Provider Name | Wynetta J Fletcher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720070048 PECOS PAC ID: 3971416421 Enrollment ID: I20031111000010 |
News Archive
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.
T cells are key players in the immune response to HIV, which are able to delete infected cells. This capacity is used for vaccine development against HIV. "To date however, success of this strategy remains elusive. Our understanding of T cell efficacy is still limited, and we need to identify precise T cell correlates of protection that could guide rationale vaccine design", says Victor Appay, Group leader HIV Pathogenesis and Immunosenescence, Hopital Pitie-Salpetriere, Paris, at the 2nd European Congress of Immunology ECI 2009 in Berlin.
VertiFlex, Inc., a leading innovator of advanced minimally invasive spinal surgery technologies, today announced that the U.S. Patent and Trademark Office has awarded five additional key patents covering the design and implantation method for its unique interspinous spacer technology. The five U.S. patent numbers are 8,012,207, 8,123,807, 8,123,782, 8,128,662, and 8,152,837.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 2 days ago
| Provider Name | Sarah J Campbell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477896306 PECOS PAC ID: 4183861297 Enrollment ID: I20130509000302 |
News Archive
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.
T cells are key players in the immune response to HIV, which are able to delete infected cells. This capacity is used for vaccine development against HIV. "To date however, success of this strategy remains elusive. Our understanding of T cell efficacy is still limited, and we need to identify precise T cell correlates of protection that could guide rationale vaccine design", says Victor Appay, Group leader HIV Pathogenesis and Immunosenescence, Hopital Pitie-Salpetriere, Paris, at the 2nd European Congress of Immunology ECI 2009 in Berlin.
VertiFlex, Inc., a leading innovator of advanced minimally invasive spinal surgery technologies, today announced that the U.S. Patent and Trademark Office has awarded five additional key patents covering the design and implantation method for its unique interspinous spacer technology. The five U.S. patent numbers are 8,012,207, 8,123,807, 8,123,782, 8,128,662, and 8,152,837.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 2 days ago
| Provider Name | Yasmin Majumder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811305766 PECOS PAC ID: 1254559446 Enrollment ID: I20140829002132 |
News Archive
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.
T cells are key players in the immune response to HIV, which are able to delete infected cells. This capacity is used for vaccine development against HIV. "To date however, success of this strategy remains elusive. Our understanding of T cell efficacy is still limited, and we need to identify precise T cell correlates of protection that could guide rationale vaccine design", says Victor Appay, Group leader HIV Pathogenesis and Immunosenescence, Hopital Pitie-Salpetriere, Paris, at the 2nd European Congress of Immunology ECI 2009 in Berlin.
VertiFlex, Inc., a leading innovator of advanced minimally invasive spinal surgery technologies, today announced that the U.S. Patent and Trademark Office has awarded five additional key patents covering the design and implantation method for its unique interspinous spacer technology. The five U.S. patent numbers are 8,012,207, 8,123,807, 8,123,782, 8,128,662, and 8,152,837.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 2 days ago
News Archive
Long-term research that was initiated at UCLA's Jonsson Comprehensive Cancer Center on lymphatic mapping and sentinel-node biopsy, techniques for detecting the earliest spread (metastasis) of melanoma, the deadliest form of skin cancer, has confirmed that these techniques significantly prolong patients' disease-free and melanoma-specific survival over the traditional observational "watch and wait" techniques.
T cells are key players in the immune response to HIV, which are able to delete infected cells. This capacity is used for vaccine development against HIV. "To date however, success of this strategy remains elusive. Our understanding of T cell efficacy is still limited, and we need to identify precise T cell correlates of protection that could guide rationale vaccine design", says Victor Appay, Group leader HIV Pathogenesis and Immunosenescence, Hopital Pitie-Salpetriere, Paris, at the 2nd European Congress of Immunology ECI 2009 in Berlin.
VertiFlex, Inc., a leading innovator of advanced minimally invasive spinal surgery technologies, today announced that the U.S. Patent and Trademark Office has awarded five additional key patents covering the design and implantation method for its unique interspinous spacer technology. The five U.S. patent numbers are 8,012,207, 8,123,807, 8,123,782, 8,128,662, and 8,152,837.
Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 2 days ago
Bee Well Counseling Service Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 124 Smokey Mountain Ln, Morehead, KY 40351 Phone: 606-748-7244 | |
Faithful Recovery Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 224 E Main St, Morehead, KY 40351 Phone: 606-548-1728 | |
Consulting, Counseling And Training, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 55 Gene White Ln, Morehead, KY 40351 Phone: 606-356-7094 | |
St. Claire Medical Center, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 316 W 2nd St, Morehead, KY 40351 Phone: 606-784-3771 Fax: 606-783-6847 | |
Brightfuturenow Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5552 Big Perry Rd, Morehead, KY 40351 Phone: 859-312-7229 Fax: 859-309-0353 | |
St Claire Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 555 W Sun St, Morehead, KY 40351 Phone: 606-783-6805 Fax: 606-783-6869 |